KeyBanc analyst Matthew Gillmor raised the firm’s price target on Tenet Healthcare (THC) to $250 from $225 and keeps an Overweight rating on the shares. The firm notes the company’s Q4 results were good, 2026 guidance was better, and the stock reaction was surprisingly strong.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare Earnings Call Balances Growth and Risks
- Morning Movers: Unity plunges following fourth quarter report
- Tenet Healthcare reports Q4 adjusted EPS $4.70, consensus $4.05
- Tenet Healthcare sees FY26 adjusted EBITDA $4.485B-$4.785B
- Tenet Healthcare sees FY26 adjusted EPS $16.19-$18.47, consensus $16.46